Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Bibliografske podrobnosti
Main Authors:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2020

Podobne knjige/članki

Lipid-modifying agents, from statins to PCSK9 inhibitors
od: Preiss, D, et al.
Izdano: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
od: Sanjiv Gupta
Izdano: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
od: Caleyachetty, R, et al.
Izdano: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
od: K. O. Shnaider, et al.
Izdano: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
od: Konstantinos Koskinas, et al.
Izdano: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
od: Christopher LaFratte, et al.
Izdano: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
od: Nissen, SE, et al.
Izdano: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
od: Mohsin Haseeb, et al.
Izdano: (2023-03-01)

JACC: Asia
od: Jian'an Wang, MD, PhD
Izdano: (2021-06-01)

JACC: Asia
od: Valentin Fuster, MD, PhD, et al.
Izdano: (2021-06-01)

The PCSK9 decade
od: Gilles Lambert, et al.
Izdano: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
od: Mbikay Majambu, et al.
Izdano: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
od: Shuai Wang, et al.
Izdano: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
od: Ying Xiao, et al.
Izdano: (2022-11-01)

PCSK9 inhibitors
od: Baris Gencer, et al.
Izdano: (2015-04-01)

JACC: Case Reports
od: Julia Grapsa, MD, PhD, et al.
Izdano: (2019-08-01)

JACC: Case Reports
od: Julia Grapsa, MD, PhD, et al.
Izdano: (2020-06-01)

JACC: Case Reports
od: Purvi Parwani, MBBS, MPH, et al.
Izdano: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
od: Preiss, D, et al.
Izdano: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
od: Maram H. Abduljabbar
Izdano: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
od: Sliz, E, et al.
Izdano: (2018)

Vision for JACC: Case Reports
od: Julia Grapsa, MD, PhD
Izdano: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
od: Armitage, J, et al.
Izdano: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
od: A. V. Blokhina, et al.
Izdano: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
od: Markus Mohaupt
Izdano: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
od: Bijay Mukesh Jeswani, et al.
Izdano: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
od: Naoto Kuyama, et al.
Izdano: (2021-06-01)

Introducing JACC: Basic to Translational Science
od: Douglas L. Mann, MD, et al.
Izdano: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
od: Weiqi Zeng, et al.
Izdano: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
od: Preiss, D, et al.
Izdano: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
od: Dennis T. Ko, et al.
Izdano: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
od: Tiny Nair
Izdano: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
od: Martin Jozef Péč, et al.
Izdano: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
od: Caroline Coppinger BS, et al.
Izdano: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
od: L. Castilla-Guerra, et al.
Izdano: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
od: A. Yu. Filatova, et al.
Izdano: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
od: Marianna Puccini, et al.
Izdano: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
od: Blom DJ, et al.
Izdano: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
od: Zinan ZHAO, et al.
Izdano: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
od: Lillian Smith, et al.
Izdano: (2016-03-01)